NO20034007D0 - N-fenylarylsulfonamidforbindelse, legemiddel inneholdende forbindelsen somaktiv bestanddel, mellomprodukt for forbindelsen, ogfremgangsmåter for fremstilling av samme - Google Patents
N-fenylarylsulfonamidforbindelse, legemiddel inneholdende forbindelsen somaktiv bestanddel, mellomprodukt for forbindelsen, ogfremgangsmåter for fremstilling av sammeInfo
- Publication number
- NO20034007D0 NO20034007D0 NO20034007A NO20034007A NO20034007D0 NO 20034007 D0 NO20034007 D0 NO 20034007D0 NO 20034007 A NO20034007 A NO 20034007A NO 20034007 A NO20034007 A NO 20034007A NO 20034007 D0 NO20034007 D0 NO 20034007D0
- Authority
- NO
- Norway
- Prior art keywords
- compound
- methyl
- preparing
- processes
- active ingredient
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- -1 5-methyl-2-furyl Chemical group 0.000 abstract 1
- 206010036018 Pollakiuria Diseases 0.000 abstract 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 abstract 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 abstract 1
- 208000026723 Urinary tract disease Diseases 0.000 abstract 1
- 208000012931 Urologic disease Diseases 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000002221 antipyretic Substances 0.000 abstract 1
- 229940125716 antipyretic agent Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 230000027939 micturition Effects 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 208000014001 urinary system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001068498 | 2001-03-12 | ||
| JP2001281569 | 2001-09-17 | ||
| JP2002007760 | 2002-01-16 | ||
| PCT/JP2002/002245 WO2002072564A1 (en) | 2001-03-12 | 2002-03-11 | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20034007D0 true NO20034007D0 (no) | 2003-09-10 |
| NO20034007L NO20034007L (no) | 2003-11-12 |
| NO329682B1 NO329682B1 (no) | 2010-11-29 |
Family
ID=27346214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034007A NO329682B1 (no) | 2001-03-12 | 2003-09-10 | N-fenylarylsulfonamidforbindelse, og antagonist av EP1 reseptor og farmasoytisk preparat omfattende forbindelsen som aktiv bestanddel |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7235667B2 (no) |
| EP (2) | EP1369419B1 (no) |
| JP (3) | JP3555620B2 (no) |
| KR (1) | KR100886854B1 (no) |
| CN (1) | CN1294126C (no) |
| AT (2) | ATE362924T1 (no) |
| AU (1) | AU2002238855B2 (no) |
| BR (1) | BR0208027A (no) |
| CA (1) | CA2439604C (no) |
| CZ (1) | CZ304035B6 (no) |
| DE (1) | DE60220255T2 (no) |
| DK (2) | DK1612208T3 (no) |
| ES (1) | ES2286230T3 (no) |
| HU (1) | HU230056B1 (no) |
| IL (2) | IL157701A0 (no) |
| MX (1) | MXPA03008134A (no) |
| NO (1) | NO329682B1 (no) |
| NZ (1) | NZ528120A (no) |
| PL (1) | PL218750B1 (no) |
| PT (2) | PT1369419E (no) |
| RU (1) | RU2299202C2 (no) |
| TW (1) | TWI317359B (no) |
| WO (1) | WO2002072564A1 (no) |
| ZA (1) | ZA200306884B (no) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022549A1 (ja) * | 2002-09-09 | 2004-03-18 | Ono Pharmaceutical Co., Ltd. | ４−メチル−１，３−チアゾール−２−イルスルホニルハライドの製造方法 |
| DK1603893T3 (da) * | 2003-01-29 | 2008-09-08 | Asterand Uk Ltd | EP4 -Receptorantagonister |
| GB0317500D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Treatment of bph |
| US20070167500A1 (en) * | 2003-06-27 | 2007-07-19 | Takayuki Maruyama | Remedy for urinary tract diseases |
| GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| TW200612938A (en) * | 2004-07-05 | 2006-05-01 | Chugai Pharmaceutical Co Ltd | Remedy for hyperactive bladder |
| JP2008189549A (ja) * | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| JP2009057282A (ja) * | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
| TW200817319A (en) | 2006-08-10 | 2008-04-16 | Astellas Pharma Inc | Sulfonamide compound or salt thereof |
| ES2437323T3 (es) | 2007-02-16 | 2014-01-10 | Ono Pharmaceutical Co., Ltd. | Agente terapéutico para trastornos de la micción |
| HRP20120363T1 (hr) * | 2007-08-01 | 2012-05-31 | Taisho Pharmaceutical Co. | Inhibitor vezivanja s1p1 |
| EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
| CA2728511A1 (en) * | 2008-06-23 | 2009-12-30 | Astellas Pharma Inc. | Sulfonamide compounds or salts thereof |
| TW201107309A (en) * | 2009-07-27 | 2011-03-01 | Kissei Pharmaceutical | Indole derivatives, or the pharmaceutically acceptable salts |
| JP2013532688A (ja) * | 2010-07-26 | 2013-08-19 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃｙｐ１７阻害剤として有用なスルホンアミド化合物 |
| JP5363636B2 (ja) * | 2011-10-21 | 2013-12-11 | ファイザー・リミテッド | 新規な塩および医学的使用 |
| US20140039004A1 (en) * | 2012-07-31 | 2014-02-06 | Ono Pharmaceutical Co., Ltd. | Method of treating of gastroesophageal reflux disease |
| WO2015166115A1 (es) * | 2014-04-30 | 2015-11-05 | Industrias Peñalver, S.L. | Cabezal concéntrico programable para aplicación líquida en tapas multiformato |
| MY194015A (en) * | 2015-11-13 | 2022-11-08 | Daewoong Pharmaceutical Co Ltd | Sodium channel blocker |
| RU2659955C1 (ru) * | 2017-10-26 | 2018-07-04 | Галина Ильхамовна Лукина | Способ диагностики высоких гастроэзофагеальных рефлюксов |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2419923A1 (de) * | 1973-04-28 | 1974-11-28 | Fujisawa Pharmaceutical Co | Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel |
| JPS5748534B2 (no) * | 1974-03-04 | 1982-10-16 | ||
| DE2555048A1 (de) * | 1975-12-06 | 1977-06-30 | Pfersee Chem Fab | Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen |
| JPS5293469A (en) | 1976-02-02 | 1977-08-05 | Fuji Photo Film Co Ltd | Method of curing gelatin |
| JPH05293469A (ja) | 1992-04-17 | 1993-11-09 | Toda Constr Co Ltd | 滅菌精製水の製造方法およびその装置 |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| WO2000069465A1 (en) * | 1999-05-12 | 2000-11-23 | Ono Pharmaceutical Co., Ltd. | Anticancer agents containing ep1 antagonists as the active ingredient |
| WO2001008674A1 (en) | 1999-07-29 | 2001-02-08 | Ono Pharmaceutical Co., Ltd. | Sulfonamide derivatives and remedies for allodynia |
| US7335776B2 (en) | 2001-03-14 | 2008-02-26 | Ono Pharmaceutical Co., Ltd. | Remedies for depression containing EP1 antagonist as the active ingredient |
-
2002
- 2002-03-11 CA CA2439604A patent/CA2439604C/en not_active Expired - Fee Related
- 2002-03-11 RU RU2003127677/04A patent/RU2299202C2/ru not_active IP Right Cessation
- 2002-03-11 IL IL15770102A patent/IL157701A0/xx unknown
- 2002-03-11 KR KR1020037011921A patent/KR100886854B1/ko not_active Expired - Fee Related
- 2002-03-11 CZ CZ20032452A patent/CZ304035B6/cs not_active IP Right Cessation
- 2002-03-11 HU HU0400155A patent/HU230056B1/hu not_active IP Right Cessation
- 2002-03-11 WO PCT/JP2002/002245 patent/WO2002072564A1/ja not_active Ceased
- 2002-03-11 DE DE60220255T patent/DE60220255T2/de not_active Expired - Lifetime
- 2002-03-11 TW TW091104451A patent/TWI317359B/zh not_active IP Right Cessation
- 2002-03-11 JP JP2002571480A patent/JP3555620B2/ja not_active Expired - Fee Related
- 2002-03-11 PL PL365100A patent/PL218750B1/pl unknown
- 2002-03-11 US US10/471,673 patent/US7235667B2/en not_active Expired - Fee Related
- 2002-03-11 PT PT02705096T patent/PT1369419E/pt unknown
- 2002-03-11 EP EP02705096A patent/EP1369419B1/en not_active Expired - Lifetime
- 2002-03-11 AT AT02705096T patent/ATE362924T1/de active
- 2002-03-11 ES ES02705096T patent/ES2286230T3/es not_active Expired - Lifetime
- 2002-03-11 DK DK05109059.5T patent/DK1612208T3/da active
- 2002-03-11 DK DK02705096T patent/DK1369419T3/da active
- 2002-03-11 MX MXPA03008134A patent/MXPA03008134A/es active IP Right Grant
- 2002-03-11 NZ NZ528120A patent/NZ528120A/en not_active IP Right Cessation
- 2002-03-11 PT PT05109059T patent/PT1612208E/pt unknown
- 2002-03-11 AU AU2002238855A patent/AU2002238855B2/en not_active Ceased
- 2002-03-11 EP EP05109059A patent/EP1612208B1/en not_active Expired - Lifetime
- 2002-03-11 AT AT05109059T patent/ATE522513T1/de active
- 2002-03-11 BR BR0208027-3A patent/BR0208027A/pt not_active IP Right Cessation
- 2002-03-11 CN CNB028097904A patent/CN1294126C/zh not_active Expired - Fee Related
-
2003
- 2003-09-02 IL IL157701A patent/IL157701A/en not_active IP Right Cessation
- 2003-09-03 ZA ZA2003/06884A patent/ZA200306884B/en unknown
- 2003-09-10 NO NO20034007A patent/NO329682B1/no not_active IP Right Cessation
- 2003-12-24 JP JP2003427226A patent/JP3741120B2/ja not_active Expired - Fee Related
-
2005
- 2005-08-26 JP JP2005245763A patent/JP4432051B2/ja not_active Expired - Fee Related
- 2005-09-30 US US11/239,406 patent/US7629369B2/en not_active Expired - Fee Related
-
2009
- 2009-10-21 US US12/603,194 patent/US8088802B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20034007D0 (no) | N-fenylarylsulfonamidforbindelse, legemiddel inneholdende forbindelsen somaktiv bestanddel, mellomprodukt for forbindelsen, ogfremgangsmåter for fremstilling av samme | |
| DE60018064D1 (de) | Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar) | |
| JP2010530431A5 (no) | ||
| GEP20094723B (en) | Tetraazabenzo [e] azulene derivatives and analogs thereof | |
| NO20032510L (no) | Organiske forbindelser | |
| BG106095A (bg) | Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици | |
| NZ514661A (en) | alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions | |
| HK1046405A1 (zh) | 作为nmda受体拮抗剂用於治疗疼痛的取代的1，5-二氢吡咯-2-酮衍生物 | |
| SE0102036D0 (sv) | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof | |
| ATE404211T1 (de) | Xenon als nmda-antogonist zur neuroprotektion | |
| WO2003063787A3 (en) | Non-steroidal analogs of 2-methoxyestradiol | |
| EP1348698A4 (en) | SUBSTITUTED CARBOXYLENE DERIVATIVES | |
| DE60022895D1 (de) | Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| DK1228758T3 (da) | Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom | |
| NO20050667L (no) | N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes | |
| WO1999004770A3 (en) | A pharmaceutical composition active in reducing production of mcp-1 protein | |
| WO2003018010A1 (en) | Preventive and/or remedial agent for disease attributable to arteriosclerotic activity | |
| AR016070A1 (es) | Forma polimorfica cristalina 1 del compuesto sal acetato de metil-n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una protein | |
| ATE247963T1 (de) | Medikament zur behandlung von glaukoma und ischämischer retinopathie | |
| EP1172106A3 (en) | Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists | |
| JP2003012516A5 (no) | ||
| JP2006503049A5 (no) | ||
| EP1466909A4 (en) | HALOGENBENZYLAMINOPROPIONSÄUREDERIVATE | |
| TH84975A (th) | อนุพันธ์ไซยาโนไพริดีนชนิดใหม่ที่มีประโยชน์ในการบำบัดมะเร็งและความผิดปกติอื่นๆ | |
| BR9814660A (pt) | compostos de éter cìclico piperidinilaminometil-trifluorometìlico como antagonista da substáncia p e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |